Biobras rose from a start-up to become the world's fourth largest insulin producer.
Between 1995 and 2000, shares of Biobras appreciated 1512%, the third highest share price appreciation of any company on the BOVESPA during that period. Biobras was also the best performing investment ever made by BNDESPAR, the investment arm of Brazil's National Economic Development Bank. Along the way, Biobras successfully achieved two liquidity events, becoming a publicly traded company and, more recently, being acquired by the Danish pharmaceutical giant, Novo Nordisk.
Novo Nordisk has the broadest diabetes product portfolio in the industry. They also have a leading position in areas such as haemostasis management, growth hormone therapy and hormone replacement therapy.
Novo Nordisk Regional Office Latin America (LARO)
Head of Office: Mr Sergio K. Noschang (SKNO)
Address: Av. Francisco Matarazzo, 1 500, Ed. New York, 13th floor 'Agua Braca Sao Paulo - SP, 05001-400, Brazil
Phone: +55 11 3868 9090
Fax: +55 11 3868 9089
* Novo Nordisk is a healthcare company and world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. Headquartered in Denmark, Novo Nordisk employs approximately 21,600 full-time employees in 78 countries, and markets its products in 179 countries.
Saturday, January 14, 2006
